

COVID-19 RAPID ANTIGEN TESTING NOTICE

Chevron Canada Resources and Chevron Canada Limited (“Chevron Canada”) are committed to protecting the health and safety of its workforce personnel in accordance with its occupational health and safety obligations, which includes taking every precaution that is reasonable in the circumstances for the protection of its workers.

Current safeguards have proven very effective at minimizing exposure to COVID-19 within our workforce, and we thank each and every worker for their diligence in following the 3 W’s (wear a mask, wash your hands, watch your distance). However, given the outbreak at the Kaybob Duvernay operation at the end of 2020 and new, more infectious variants of the COVID-19 virus, Chevron Canada has determined that it needs to take additional steps to protect the health and safety of certain high-risk groups in its workforce.

We have been working with our third-party medical provider, Industrial Paramedic Services (IPS), to secure access to the PanBio™ COVID-19 Rapid Antigen Test. These are manufactured by Abbott, which has, at this time, secured kits for three to six months of testing. The PanBio™ COVID-19 Rapid Antigen Test is an antigen test which detects COVID-19 from nasal swabs and provides results in approximately 15 minutes. [See here for additional information](#) on the PanBio™ COVID-19 Rapid Antigen Test.

Chevron Canada has developed a [COVID-19 Testing Policy \(the “Policy”\)](#) that will apply to workers at Chevron Canada’s Kaybob Duvernay worksites. Chevron Canada will be providing both: 1) symptomatic worker testing, and 2) pre-access site testing. The Policy defines those workers who will be subject to testing, and what happens in the event of positive and negative results.

Commencing on March 15, 2021, workers at the Kaybob Duvernay (KD) site that fit within the high-risk groups defined in the Policy will be subject to testing upon commencement of their rotational shift. Each worker who will be subject to testing will be advised by **their supervisor** prior to commencing their next rotational shift. Refusal to participate in testing may result in the worker not being admitted to the site. Any worker who is concerned about submitting a pre-site access test must contact their supervisor in advance of the worker’s first shift following March 15, 2021. Failure to raise concerns prior to attending site will result in access to the site being denied.

Our ability to offer rapid tests to workers prior to accessing the KD site will help Chevron Canada keep those higher-risk workers who work and live in close-proximity safe and healthy, as well as helping to ensure business continuity. Access to test kits for symptomatic workers will allow workers to know their test results in 15 minutes, instead of waiting several days, and will enable Chevron Canada to commence contact tracing immediately upon receipt of the test results, thereby limiting potential further spread of the COVID-19 virus. Chevron Canada is committed to all workers returning to their homes safe and healthy each day.

Should you have any questions regarding this notice please contact Andrea Schnare at (403) 234-5025 or Andrea.Schnare@chevron.com or Mike Meynberg at (587) 416-1926 or michaelmeynberg@chevron.com.